102 related articles for article (PubMed ID: 15621773)
1. Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia.
Clavio M; Pierri I; Venturino C; Garrone A; Canepa L; Miglino M; Varaldo R; Ballerini F; Michelis GL; Balocco M; Abdall N; Gatto S; Gobbi M
Leuk Lymphoma; 2004 Dec; 45(12):2527-30. PubMed ID: 15621773
[No Abstract] [Full Text] [Related]
2. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
[TBL] [Abstract][Full Text] [Related]
3. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
4. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
5. Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.
Pea F; Russo D; Michieli M; Damiani D; Fanin R; Michelutti A; Michelutti T; Piccolrovazzi S; Baccarani M; Furlanut M
Clin Pharmacokinet; 2003; 42(9):851-62. PubMed ID: 12882589
[TBL] [Abstract][Full Text] [Related]
6. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.
Thomas MB; Koller C; Yang Y; Shen Y; O'Brien S; Kantarjian H; Davis J; Estey E
Leukemia; 2003 May; 17(5):990-3. PubMed ID: 12750721
[No Abstract] [Full Text] [Related]
7. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
8. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
9. [Experience with fludarabine treatment and review of the literature].
Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.
Carol H; Fan MM; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB
Pediatr Blood Cancer; 2015 Jan; 62(1):65-71. PubMed ID: 25203866
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
Gergis U; Roboz G; Shore T; Ritchie E; Mayer S; Wissa U; McKenna M; Christos P; Pearse R; Mark T; Scandura J; van Besien K; Feldman E
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1040-5. PubMed ID: 23648237
[TBL] [Abstract][Full Text] [Related]
12. Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.
Medeiros BC
Acta Haematol; 2014; 131(4):200-1. PubMed ID: 24296429
[No Abstract] [Full Text] [Related]
13. Fludarabine and high dose cytarabine (FLA): a well tolerated salvage regimen in acute myeloid leukaemia.
Strickland AH; Seymour C; Prince HM; Wolf M; Juneja S; Januszewicz EH
Aust N Z J Med; 1999 Aug; 29(4):556-8. PubMed ID: 10868535
[No Abstract] [Full Text] [Related]
14. Outcomes of Substituting Oral Fludarabine for Intravenous Fludarabine in Combination with Cytarabine and Filgrastim for Treatment of Primary Refractory or Relapsed Acute Leukemias.
Demichelis-Gómez R; Crespo-Solís E; Pérez-Jacobo LF; Valencia-Rocha UR; Rosas-López A
Rev Invest Clin; 2015; 67(5):287-95. PubMed ID: 26696332
[TBL] [Abstract][Full Text] [Related]
15. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
[TBL] [Abstract][Full Text] [Related]
18. Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Horstmann MA; Hassenpflug WA; zur Stadt U; Escherich G; Janka G; Kabisch H
Haematologica; 2005 Dec; 90(12):1701-3. PubMed ID: 16330449
[TBL] [Abstract][Full Text] [Related]
19. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
[TBL] [Abstract][Full Text] [Related]
20. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]